About this item:

170 Views | 136 Downloads

Author Notes:

Betsy Sleath, Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB# 7573, Chapel Hill, NC 27599-7573, USA. Email: betsy_sleath@unc.edu.

Betsy Sleath, Robyn Sayner, and Delesha Carpenter contributed to drafting the article.

Kelly Muir, Susan Blalock, and Alan Robin revised it critically for important intellectual content.

Betsy Sleath, Kelly Muir, Annette Giangiacomo, Mary Elizabeth Hartnett, and Alan Robin contributed to conception and design of study.

Kelly Muir, Annette Giangiacomo, Mary Elizabeth Hartnett, and Alan Robin contributed to acquisition of data.

Betsy Sleath, Susan Blalock, Michelle Vitko, and Robyn Sayner contributed to analysis and interpretation of data.

All authors gave final approval of the submitted version of the article.

National Institutes of Health had no role in the design or conduct of this research.

Drs. Sleath, Blalock, Carpenter, Muir, and Sayner indicate no conflict of interest.

Dr. Robin has been a consultant for Biolight, Lupin Pharmaceuticals, and Sucampo and he does paid lectures for Merck and Allergan.

He has been a consultant and has stock options in Glaucos. Dr. Robin is on the board of Aerie Pharmaceuticals.

Dr. Hartnett is a consultant for Axikin Pharmaceuticals.

Dr. Muir receives salary support from a Veterans Affairs Health Services Research & Development Career Development Award.

Subjects:

Research Funding:

This project was supported by grant EY018400 from the National Eye Institute and by grant 1UL1TR001111 from the National Center of Research Resources, National Institutes of Health.

Dr. Hartnett was also supported by National Institutes of Health grants EY015130 and EY017011.

Keywords:

  • Science & Technology
  • Social Sciences
  • Life Sciences & Biomedicine
  • Public, Environmental & Occupational Health
  • Social Sciences, Interdisciplinary
  • Social Sciences - Other Topics
  • Glaucoma
  • Quality-of-life
  • Vision loss
  • Communication
  • Patient question-asking
  • CENTERED COMMUNICATION
  • MEDICATION ADHERENCE
  • PHYSICIAN GENDER
  • PRIMARY-CARE
  • PREVALENCE
  • EYEDROPS

Glaucoma patient-provider communication about vision quality-of-life

Tools:

Journal Title:

Patient Education and Counseling

Volume:

Volume 100, Number 4

Publisher:

, Pages 703-709

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Objective The purpose of this study was to: (a) describe the extent to which ophthalmologists and glaucoma patients discuss vision quality-of-life during office visits, and (b) examine the association between patient and ophthalmologist characteristics and provider-patient communication about vision quality-of-life. Methods Patients with glaucoma who were newly prescribed or on glaucoma medications were recruited at six ophthalmology clinics. Patients’ visits were video-tape recorded and quality-of-life communication variables were coded. Generalized estimating equations were used to analyze the data. Results Two hundred and seventy-nine patients participated. Specific glaucoma quality-of-life domains were discussed during only 13% of visits. Older patients were significantly more likely to discuss one or more vision quality-of-life domains th an younger patients. African American patients were significantly less likely to make statements about their vision quality-of-life and providers were less likely to ask them one or more vision quality-of-life questions than non-African American patients. Conclusion Eye care providers and patients infrequently discussed the patient's vision quality-of-life during glaucoma visits. African American patients were less likely to communicate about vision quality-of-life than non-African American patients. Practice implications Eye care providers should make sure to discuss vision quality-of-life with glaucoma patients.

Copyright information:

© 2016 Elsevier Ireland Ltd

Export to EndNote